Delivery Order SPE2DB24D2003-SPE2DB25FXLJ5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,178.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract was competitively awarded without set-aside designation and is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) valued at $1,037.97. This firm fixed-price delivery order, with an ultimate completion date of August 18, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance...
- The Defense Logistics Agency awarded a $2,357.92 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xcopri 25 mg tablets (30-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 6, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The contract involves no set-aside designation and identifies Conshohocken, Pennsylvania, as the place of performance,...
- The Defense Logistics Agency awarded a delivery order valued at $3,652.69 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 200 mg tablets, with performance completion targeted for August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,768.44 for XCOPRI 150 mg tablets (30-count units) with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a...
- The Defense Department's Medical Supply Chain awarded a $1,286.70 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XCOPRI 50-100 MG Titration Pak pharmaceutical supplies. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 29, 2025, with performance at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,569.42 on July 28, 2025, for Xcopri 50 mg tablets (30-count supply). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract under the company's existing pharmaceutical supply agreements with DLA. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of XCOPRI 50 MG tablets (30-count packages) valued at $7,622.85. This firm fixed-price delivery order represents a non-competitive award and carries an ultimate completion date of August 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,624.86 to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 200 mg, with an ultimate completion date of August 13, 2025. This competitive award, issued on August 12, 2025, employs firm fixed pricing and carries no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor and...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLJ5Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 5, 2025, by the Defense Logistics Agency for the supply of Xcopri 100 mg tablets (30-count package) with a ceiling value of $4,846.14. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance for this delivery order is the company's corporate office location in Conshohocken, Pennsylvania. This award reflects AmerisourceBergen's established role as a critical vendor within the Defense Logistics Agency's pharmaceutical supply chain, supporting military and veteran healthcare systems with a comprehensive portfolio of medications and medical supplies. Xcopri (cenobamate) is an anti-seizure medication used in neurological treatment, consistent with the company's broader federal contract portfolio that includes specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The rapid completion timeline and single-order nature of this delivery order demonstrates the efficiency and flexibility of the underlying indefinite delivery vehicle in meeting urgent federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 8/5/25 |